

BAXTER INTERNATIONAL INC.
Key Product Line Sales by US and International
Periods Ending March 31, 2010 and 2009
(unaudited)
(\$ in millions)

	Q1 2010			Q1 2009			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	\$222	\$288	\$510	\$211	\$240	\$451	5%	20%	13%
Plasma Proteins	94	198	292	98	176	274	(4%)	13%	7%
Antibody Therapy	223	99	322	250	87	337	(11%)	14%	(4%)
Regenerative Medicine	62	57	119	55	44	99	13%	30%	20%
Other ¹	9	110	119	8	83	91	13%	33%	31%
Total BioScience	\$610	\$752	\$1,362	\$622	\$630	\$1,252	(2%)	19%	9%
Medication Delivery									
IV Therapies	\$124	\$267	\$391	\$108	\$236	\$344	15%	13%	14%
Global Injectables	250	201	451	208	163	371	20%	23%	22%
Infusion Systems	122	87	209	122	77	199	0%	13%	5%
Anesthesia	82	45	127	73	36	109	12%	25%	17%
Other ¹		3	4	3	9	12	(67%)	(67%)	(67%)
Total Medication Delivery	\$579	\$603	\$1,182	\$514	\$521	\$1,035	13%	16%	14%
Renal									
PD Therapy	\$76	\$398	\$474	\$71	\$349	\$420	7%	14%	13%
HD Therapy	19	91	110	21	74	95	(10%)	23%	16%
Total Renal	\$95	\$489	\$584	\$92	\$423	\$515	3%	16%	13%
Baxter excluding Transfusion Therapies	\$1,284	\$1,844	\$3,128	\$1,228	\$1,574	\$2,802	5%	17%	12%
Transfusion Therapies²	\$9	\$3	\$12	\$13	\$9	\$22	(31%)	(67%)	(45%)
Total Baxter	\$1,293	\$1,847	\$3,140	\$1,241	\$1,583	\$2,824	4%	17%	11%

¹ Principally includes vaccines and sales of plasma to third parties.

² Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.